Controversies in Neurology: Why Monoamine Oxidase B Inhibitors Could Be a Good Choice for the Initial Treatment of Parkinson's Disease

BMC Neurology - United Kingdom
doi 10.1186/1471-2377-11-112
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

The PPARγ Agonist Pioglitazone Is Effective in the MPTP Mouse Model of Parkinson's Disease Through Inhibition of Monoamine Oxidase B

British Journal of Pharmacology
Pharmacology
2008English

Praziquantel Could Be the Appropriate Choice for the Diagnostic Treatment of Schistosomiasis

Internal Medicine
Internal MedicineMedicine
2020English

Structure-Activity Relationship Analysis of 3-Phenylcoumarin-Based Monoamine Oxidase B Inhibitors

Frontiers in Chemistry
Chemistry
2018English

Effects of Monoamine Oxidase Inhibitors on Cocaine Discrimination in Rats

Behavioural Pharmacology
PsychiatryMental HealthPharmacology
2006English

Erratum To: Prescribing Pattern and Resource Utilization of Monoamine Oxidase-B Inhibitors in Parkinson Treatment: Comparison Between Rasagiline and Selegiline

Neurological Sciences
DermatologyMedicinePsychiatryNeurologyMental Health
2016English

Human Monoamine Oxidase A: Structure and Control of Opening the Entry for Substrates/Inhibitors

Acta Crystallographica Section A Foundations of Crystallography
2008English

Design, Synthesis and Pharmacological Evaluation of New Coumarin Derivatives as Monoamine Oxidase a and B Inhibitors

2008English

Authors' Response to "Praziquantel Could Be the Appropriate Choice for the Diagnostic Treatment of Schistosomiasis"

Internal Medicine
Internal MedicineMedicine
2020English

Synthesis and Evaluation of Iodinated Benzamide Derivative as Selective and Reversible Monoamine Oxidase B Inhibitors.

Chemical and Pharmaceutical Bulletin
MedicineDrug DiscoveryChemistry
1992English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy